|
Retrospective, observational analysis of real-world safety outcomes in sacituzumab govitecan (SG)-treated patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC). |
|
|
Consulting or Advisory Role - Bristol Myers Squibb; Pfizer; Pfizer-Myovant; Sanofi/Aventis; Totus Medicines |
Research Funding - Gilead Sciences; Karyopharm Therapeutics (Inst) |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
|
|
Employment - 4D Molecular Therapeutics (I); Genentech; Gilead Sciences; Santen (I) |
Stock and Other Ownership Interests - Gilead Sciences; Roche |
|
|
Employment - Gilead Sciences; Gilead Sciences |
Leadership - Totality Home Heath Care Agency |
Stock and Other Ownership Interests - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Gilead Sciences; Roche/Genentech |
|
|
Employment - Gilead Sciences |
Stock and Other Ownership Interests - Gilead Sciences |
Honoraria - Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Genentech/Roche; Gilead Sciences |
Stock and Other Ownership Interests - Genentech/Roche; Gilead Sciences |
Travel, Accommodations, Expenses - Gilead Sciences |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Roche |
Research Funding - Flatiron Health |
Travel, Accommodations, Expenses - Flatiron Health |
|
|
No Relationships to Disclose |